Drugs / GX-H9
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03309891 | Jan 2016 → Oct 2017 | pituitary deficiency | Genexine, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02946606 | Jan 2015 → Dec 2016 | pituitary deficiency | Genexine, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GX-H9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03309891 ↗ |
| Modality | Protein / enzyme biologic | “Long-acting Antibody-fused Recombinant Human Growth Hormone (GX-H9)” NCT02946606 ↗ |
| Route | Subcutaneous | “GX-H9 subcutaneous injections (weekly)” NCT03309891 ↗ |